Facebook Pixel Code
Abstract image of modern building window with yellow diagonal line overlaid across it
Industry Partnerships & Commercialization

Industry

SickKids innovators are on the front lines of health innovation. Leverage one of Canada's most research intensive institutes to advance your business objectives by partnering with IP&C.

Industry Partnerships

Industry partners can access the research and clinical innovation ecosystem at SickKids through:

Licensing opportunities
Source from over 100 technologies across IP&C’s comprehensive Technology Portfolio.

Start-up creation opportunities
Develop new start-up companies working in collaboration with SickKids innovators.

Sponsored research
Benefit from top-tier expertise in a variety of disciplines across SickKids’ Research Programs and clinical divisions to complement your research needs.

 

 

History of Innovation

From the invention of Pablum to the discovery of the cystic fibrosis gene, SickKids innovators have pushed the boundaries of medicine to help improve the lives of patients in Canada and around the globe. Be a part of innovation history at SickKids by partnering with IP&C.

  • 1930: Invented Pablum, the first ready-to-use enriched baby cereal that saved thousands of children from death and disease
  • 1963: Developed the Mustard surgical procedure to help correct heart problems in blue baby syndrome
  • 1989: Discovered the Cystic Fibrosis gene, paving the path for individualized medicine
  • 1993: Discovered the Wilson disease gene, allowing for better diagnosis and treatment of liver disease
  • 2004: Discovered the phenomena of copy number variation (CNVs)
  • 2010: Co-developed the Hemophilia Joint Health Score (HJHS) as a validated multi-item outcome measure for the assessment of joint health primarily designed for children with hemophilia aged 4 to 18 years old with mild joint impairment (e.g., treated with prophylaxis)
  • 2017: Co-developed the Pediatric Ulcerative Colitis Activity Index (PUCAI) as a validated multi-item outcome measure of ulcerative colitis disease activity that meets the need for non-invasive testing of paediatric patients with ulcerative colitis
  • 2019: Appointed first-ever Chair in Biomedical Informatics and Artificial Intelligence, the first of its kind at a Canadian children’s hospital

Ready to start?

Contact us to discover how to partner with IP&C.